Fig. 1 · Structure

Documents & Downloads

Fedratinib (TG-101348, SAR302503)

Cat. No. A11082 CAS 936091-26-8

JAK2/FLT3 inhibitor

TG-101348 is an orally bioavailable, ATP-competitive and selective inhibitor of Janus-associated kinase 2 with potential antineoplastic activity.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
JAK2 (Cell-free assay) 3 nM
JAK2 (V617F) (Cell-free assay) 3 nM
FLT3 (Cell-free assay) 15 nM
RET (Cell-free assay) 48 nM

Cellular Effect

Cell Line Activity Value Description Reference
BaF3 IC50 270 nM Antiproliferative activity against mouse BaF3 cells harboring JAK2 V617F mutant assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay [PMID: 32120325]
BaF3 IC50 420 nM Antiproliferative activity against mouse BaF3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay [PMID: 32120325]
HEL IC50 305 nM Antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell proliferation incubated for 72 hrs by XTT assay [PMID: 32120325]
MM1.S IC50 1 μM Antiproliferative activity against human MM1S cells after 72 hrs by trypan blue exclusion assay [PMID: 28280261]
MV4-11 EC50 79 nM Antiproliferative activity against human MV4-11 cells after 72 hrs by celltiter-blue assay [PMID: 28280261]

Fedratinib (TG-101348, SAR302503) Research Summary

This section summarizes 4 in vitro studies of Fedratinib (TG-101348, SAR302503) from 3 published references. In vitro models include hMSC-TERT; HEK293T cells.

Fedratinib (TG-101348, SAR302503) In Vitro Studies

In hMSC-TERT cells, Fedratinib had no major effects on viability at 0.3 μM and 3 μM, but decreased viability at 30 μM after 3 days. Treatment with Fedratinib at 3 µM for 3 days produced no significant changes in apoptotic cell numbers compared with DMSO-vehicle treated control cells and did not cause cell death. In HEK293T cells, Fedratinib showed concentration-dependent inhibition of SLC19A2- and SLC19A3-mediated [3H] thiamine uptake. In thermal shift assays with recombinantly purified hSLC19A3, Fedratinib showed high-affinity binding with Kd,app = 1.0 ± 0.2 μM. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Fedratinib effects on hMSC-TERT cell viability

Cell-based study · hMSC-TERT [1]

hMSC-TERT cells received continuous Fedratinib exposure. Fedratinib had no major effects on viability at 0.3 μM and 3 μM, but decreased viability at 30 μM after 3 days.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
hMSC-TERT cell viabilityReported result no major effects of Fedratinib on hMSC-TERT cell viability at doses of 0.3 μM and 3 μM. However, Fedratinib decreased hMSC-TERT cell viability at a dose of 30 μM after 3 days of treatment.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.3, 3, and 30 μM
Exposure duration
for 1, 2, and 3 days
Method
continuous exposure
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Fedratinib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.1. Effect of Fedratinib on hMSC-TERT Cell Proliferation (S4, S6, S7); 4. Materials and Methods > 4.3. Cell Viability Assay (S35, S36); Figure 1 legend (S63)

hMSC-TERT cell viability: hMSC-TERT cell viability; comparator: DMSO-vehicle-treated control cells — 2. Results > 2.1. Effect of Fedratinib on hMSC-TERT Cell Proliferation (S4, S6, S7)

Fedratinib inhibition of transporter-mediated thiamine uptake

Cell-based study · HEK293T cells [2]

In HEK293T cells, Fedratinib showed concentration-dependent inhibition of SLC19A2- and SLC19A3-mediated [3H] thiamine uptake.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SLC19A2- and SLC19A3-mediated [3H] thiamine uptakeReported result Concentration-dependent inhibitory effect of SLC19A2- and SLC19A3-mediated [3H] thiamine uptake by fedratinib[2]

Literature-Reported Treatment Conditions

Exposure duration
3 min
Vehicle
HBSS buffer
Reported limits
Not stated in the sentences used: dose, route, control.
Methods and source locations

Compound reported in the paper: Fedratinib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Inhibition of SLC19A3 by antineoplastic fedratinib (S70); Methods > [3H]-Thiamine cellular uptake assay (S206, S207); Fig. 4 legend (S267)

SLC19A2- and SLC19A3-mediated [3H] thiamine uptake: SLC19A2- and SLC19A3-mediated [3H] thiamine uptake — Fig. 4 legend (S267)

Fedratinib binding to purified thiamine transporter

Biochemical assay · recombinantly purified hSLC19A3 [3]

Recombinantly purified hSLC19A3 was exposed to Fedratinib in thermal shift assays. Fedratinib showed high-affinity binding, with Kd,app = 1.0 ± 0.2 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
apparent binding affinities at 25 °CKd,app Kd,app = 1.0 ± 0.2 μM[3]

Literature-Reported Treatment Conditions

Treatment concentration
2 μM to 2 mM
Exposure duration
30 min at room temperature
Method
supplied with the respective compounds
Vehicle
SEC buffer
Methods and source locations

Compound reported in the paper: Fedratinib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Drug interactions of SLC19A3 (S134, S153); Methods > Thermal stability measurements and binding affinity determination (S218, S219, S224, S225)

apparent binding affinities at 25 °C: apparent binding affinities at 25 °C; comparator: the apo state (Tmapo) — Results > Drug interactions of SLC19A3 (S153); Methods > Thermal stability measurements and binding affinity determination (S225)

Fedratinib effects on apoptosis in hMSC-TERT cells

Cell-based study · hMSC-TERT cells [1]

hMSC-TERT cells were treated with Fedratinib at 3 µM for 3 days. No significant changes in apoptotic cell numbers were observed compared with DMSO-vehicle treated control cells, and this concentration did not cause cell death.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
number of apoptotic cellsReported result did not observe significant changes in the number of apoptotic cells compared with DMSO-vehicle treated control cells and this concentration did not cause cell death[1]

Literature-Reported Treatment Conditions

Treatment concentration
3 µM
Exposure duration
for 3 days
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Fedratinib

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.1. Effect of Fedratinib on hMSC-TERT Cell Proliferation (S8); 4. Materials and Methods > 4.4. Measurement of Apoptosis (S39, S40); Figure 1 legend (S62, S64)

number of apoptotic cells: number of apoptotic cells; comparator: DMSO-vehicle treated control cells — 2. Results > 2.1. Effect of Fedratinib on hMSC-TERT Cell Proliferation (S8)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 936091-26-8
Applications JAK2/FLT3 inhibitor
Formula C27H36N6O3S
Molecular Weight 524.7
Synonyms SAR302503; TG101348
SMILES
CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 90 mg/mL (171.53 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Fedratinib (TG-101348, SAR302503) Research References

  1. [1] AlMuraikhi N, Alaskar H, Binhamdan S, et al. JAK2 Inhibition by Fedratinib Reduces Osteoblast Differentiation and Mineralisation of Human Mesenchymal Stem Cells. Molecules (2021). PMID: 33503825 DOI: 10.3390/molecules26030606 Source material
  2. [2] Li P, Zhu Z, Wang Y, et al. Substrate transport and drug interaction of human thiamine transporters SLC19A2/A3. Nat Commun (2024). PMID: 39738067 DOI: 10.1038/s41467-024-55359-8 Source material
  3. [3] Gabriel F, Spriestersbach L, Fuhrmann A, et al. Structural basis of thiamine transport and drug recognition by SLC19A3. Nat Commun (2024). PMID: 39358356 DOI: 10.1038/s41467-024-52872-8 Source material

Added to your cart

View Cart Checkout
Loading...